A mechanistic PK/PD model of AZD0171 (anti‐LIF) to support Phase II dose selection
Abstract AZD0171 (INN: Falbikitug) is being developed as a humanized monoclonal antibody (mAb), immunoglobulin G subclass 1 (IgG1), which binds specifically to the immunosuppressive human cytokine leukemia inhibitory factor (LIF) and inhibits downstream signaling by blocking recruitment of glycoprot...
Saved in:
Main Authors: | Azar Shahraz (Author), Mark Penney (Author), Juliana Candido (Author), Grace Opoku‐Ansah (Author), Melanie Neubauer (Author), Jim Eyles (Author), Oluwaseun Ojo (Author), Nelson Liu (Author), Nadia M. Luheshi (Author), Alex Phipps (Author), Karthick Vishwanathan (Author) |
---|---|
Format: | Book |
Published: |
Wiley,
2024-10-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Creativity in Lif
by: José Alberto Rubí-Barquero
Published: (2011) -
Changes in LIF expression on PCOS as biomarker implantation
by: Uki Retno Budihastuti, et al.
Published: (2021) -
Mechanistic PK/PD modeling to address early-stage biotherapeutic dosing feasibility questions
by: Joshuaine Grant, et al.
Published: (2023) -
LIF Upregulates Expression of NK-1R in NHBE Cells
by: Cheng-Ping Hu, et al.
Published: (2006) -
Mechanistically Coupled PK (MCPK) Model to Describe Enzyme Induction and Occupancy Dependent DDI of Dabrafenib Metabolism
by: Marco Albrecht, et al.
Published: (2022)